Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Subjects must meet the following inclusion criteria: * Be males of any race between 18 and 55 years of age * Have a body mass index between 18.0 and 32.0 kg/m2 * Be in good health, determined by no clinically significant findings from medical history * Have normal renal function, defined as estimated GFR ≥70 mL/min/1.73 m2 * Agree to use contraception * Be able to comprehend and willing to sign an ICF and to abide by the study restrictions * Have a history of a minimum of 1 bowel movement per day * Agree to refrain from donation of sperm from check-in until 90 days after discharge Main Exclusion Criteria: * Significant history or clinical manifestation of any diseases as determined by the investigator * Prolonged QTcF (\>450 msec) * Confirmed (eg, 2 consecutive measurements) systolic BP \>140 or \<90 mmHg, diastolic BP \>90 or \<50 mmHg, and pulse rate \>100 or \<45 beats per minute (bpm). * Postural tachycardia (ie, \>30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg upon standing). * Serum potassium \>upper limit of normal (5.3 mmol/L; ULN) of the reference range and serum sodium \<lower limit of normal (135 mmol/L) of the reference range * Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values \>1.2 × ULN. * A known history of porphyria, myopathy, or active liver disease * Use of any prescription medications * Corticosteroid use (systemic or extensive topical use) within 3 months prior to dosing * Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months